Table 5.

Factors associated with survival among older adults receiving chemotherapy for AML

Author (N)	Treatment	Tumor characteristics	Clinical variables	Patient Characteristics	Outcomes
Predictive models developed from treatment trials
Kantarjian et al. (N=446) [29]	Intensive	Complex karyotype	Creatinine >1.3mg/dl	Age>80 ECOG PS>1	Early mortality (8 week)
Krug et al. (N=1406) [57]	Intensive	Secondary AML or prior hematologic disease Molecular/cytogenetic risk	Body temperature Hemoglobin Platelets LDH Fibrinogen	Age	Early mortality (60 day) Complete remission
Rollig et al. (N=909) [58]	Intensive	Karyotype NPM1 mutation CD34 expression>10%	White cell count>20/μL LDH>700U/L	Age>65	Survival
Wheatley et al. (N=2208) [59]	Intensive	Cytogenetic risk group Secondary AML	White cell count	Age ECOG PS	Survival
Predictors derived from geriatric assessment studies
Deschler et al. (N=107) [12]	Non-Intensive (prospective)	Bone marrow blast % Cytogenetic risk group		Impaired ADLs KPS<80 High fatigue score HCT-CI≥3	Survival
Klepin et al. (N=74) [63]	Intensive (prospective)	Cytogenetic risk group Prior MDS	Hemoglobin	Cognitive impairment (3MS<77) Impaired physical performance (SPPB<9)	Survival
Sherman et al.(N=101) [66]	Mixed (retrospective)	Adverse cytogenetics Secondary AML		HCT-CI >1 Difficulty with strenuous activity Pain (more often versus less) ECOG PS>1	Survival

Abbreviations: LDH=lactate dehydrogenase; ECOG=Eastern Cooperative Group; PS=performance status; CR=complete remission; 3MS=modified Mini Mental State Exam; SPPB=Short physical performance battery

Adapted from Klepin et al. J Clin Oncol 2014 2014 Aug 20;32(24):2541-52.